Skip to content
★ Sign in to follow
SH

Shanghai Haohai Biological Technology Co., Ltd. - H Shares Stock: price and insider trades · Hong Kong

No insider purchase over the last 90 days. The latest, by TANG MINJIE, was filed 17 Jun 2026.

Shanghai Haohai Biological Technology Co., Ltd. - H Shares: what insiders have been doing

This page follows insider dealings at Shanghai Haohai Biological Technology Co., Ltd. - H Shares as filed with HKEX, a company from the Health Care sector. In the past year (24 October 2025 to 24 October 2026), 5 filings came from 3 insiders.

No insider sold shares on the market over the period. Instead, the filings list 3 purchases totalling €27k, made by 1 insider. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Tang Minjie filed the largest purchase, €9,188, on 12 June 2026. The buyers include 1 senior executive.

The last purchase on record was published on 17 June 2026, which is 144 days ago. Filings reach the HKEX feed a median of 3 days after the trade. The shorter that gap, the sooner other investors can see what insiders have done.

With 5 filings in twelve months, the company is more active than the median of 4 filings across the 1,315 companies we follow on the same exchange. Our records for Shanghai Haohai Biological Technology Co., Ltd. - H Shares go back to 2026, with 3 purchases and no sales on the open market in total.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. These figures are compiled from regulatory filings published by HKEX. They describe what insiders did and are not a recommendation.

Insider Decl.
5
Thresholds
n/a
Buy Volume
€26,980
3 ops. · all time
Sell Volume
n/a
n/a

Who traded when

BuySale
Tang Minjie3 buys

Since the insiders bought

  • Filed 17 Jun 2026 · 144 days ago · €8,862
    +2.1%
    Entry HK$0.42 · Close at T+90 HK$0.43

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Financial data

as of FY 2025

FY ended December 2025 · cache

HK$15.61
Analyst consensus
·
Income statement
RevenueHK$2.4B
Gross profitHK$1.7B70% margin
EBITDAHK$464.9M19% margin
Net incomeHK$251M6.6% margin
Valuation
PER (trailing)21.1x
P/Book0.6x
Beta0.45
Balance sheet & cash
Total debtHK$398.5M
Free Cash FlowHK$304M
Debt / Equity8%
Profitability & ownership
ROE2.1%
ROA1.1%
% insiders0.1%
% institutions8.1%
Last declaration on 17 June 2026
Declarations5 total
  • ▲
    DirectorExecutives
    80,600 HKD14HKEX
    5,000 shares@ HK$16.1232.8% of flowShareXHKGHKEX:DA20260616E00358
    Canonical exit: 14 Sept 2026 (T+90)
  • ▲
    DirectorExecutives
    81,000 HKD14HKEX
    5,000 shares@ HK$16.2033.1% of flowShareXHKGHKEX:DA20260612E00410
    Canonical exit: 10 Sept 2026 (T+90)
  • ▲
    DirectorExecutives
    83,340 HKD14HKEX
    5,000 shares@ HK$16.66834.1% of flowShareXHKGHKEX:DA20260611E00380
    Canonical exit: 9 Sept 2026 (T+90)
  • ●
    DirectorExecutives
    0HKEX
    10,189 sharesShareXHKGHKEX:DA20260604E00403
  • ●
    DirectorExecutives
    0HKEX
    8,408,764 sharesShareXHKGHKEX:DA20260603E00011

5 of 5 declarations

About Shanghai Haohai Biological Technology Co., Ltd. - H Shares

Shanghai Haohai Biological Technology Co., Ltd. is a company focused on the research and development of biological products. It is listed on the H Shares market.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations